This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vyavahare, N. Articles by Levy, R. J. Search for Related Content PubMed PubMed Citation Articles by Vyavahare, N. Articles by Levy, R. J.

(American Journal of Pathology. 2000;157:885-893.)
© 2000 American Society for Investigative Pathology

Regular Articles

Inhibition of Matrix Metalloproteinase Activity Attenuates Tenascin-C Production and Calcification of Implanted Purified Elastin in Rats

Narendra Vyavahare^*, Peter Lloyd Jones, Sruthi Tallapragada and Robert J. Levy

From the Department of Bioengineering,^*
Clemson University, Clemson, South Carolina; and the Division of Pediatric Cardiology Research,
Children’s Hospital of Philadelphia and the Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Elastin, a major extracellular matrix protein present in arterial walls provides elastic recoil and resilience to arteries. Elastin is prone to calcification in a number of cardiovascular diseases including atherosclerosis and bioprosthetic heart valve mineralization. We have recently shown that purified elastin when implanted subdermally in rats undergoes severe calcification. In the present study, we used this elastin implant model to investigate the molecular mechanisms underlying elastin calcification. Intense matrix metalloproteinase (MMP-2) and tenascin-C (TN-C) expression were seen in the proximity of the initial cal-cific deposits at 7 days. Gelatin zymography studies showed both MMP-2 (latent and active form) and MMP-9 expression within the implants. To investigate the role of MMPs in calcification, rats were administered a MMP inhibitor, (2S-allyl-N-hydroxy-3R-isobutyl-N-(1S-methylcarbamoyl-2-phenylethyl)-succinamide (BB-1101) by daily injection, either systemically or at the implant site. The site-specific BB-1101 administration almost completely suppressed TN-C expression, as shown by immunohistochemical staining, within the implants. The systemic BB-1101 injections also significantly reduced TN-C expression within the elastin implants. Moreover, calcification of elastin implants was significantly reduced in the site-specific administration group (5.43 ± 1.03 µg/mg Ca for BB-1101 group versus 21.71 ± 1.19 for control group, P < 0.001). Alizarin Red staining clearly showed that the elastin fibers were heavily calcified in the control group, whereas in BB-1101 group the calcification was scarce with few fibers showing initial calcification deposits. The systemic administration of BB-1101 also significantly reduced elastin calcification (28.07 ± 5.81 control versus 16.92 ± 2.56 in the BB-1101 group, P < 0.05), although less than the site-specific administration. Thus, the present studies indicate that MMPs and TN-C play a role in elastin-oriented calcification.

This article has been cited by other articles:

				C. Bouvet, S. Moreau, J. Blanchette, D. de Blois, and P. Moreau Sequential Activation of Matrix Metalloproteinase 9 and Transforming Growth Factor {beta} in Arterial Elastocalcinosis Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 856 - 862. [Abstract] [Full Text] [PDF]

				A. Simionescu, D. T. Simionescu, and N. R. Vyavahare Osteogenic Responses in Fibroblasts Activated by Elastin Degradation Products and Transforming Growth Factor-{beta}1: Role of Myofibroblasts in Vascular Calcification Am. J. Pathol., July 1, 2007; 171(1): 116 - 123. [Abstract] [Full Text] [PDF]

				J. C. Isenburg, D. T. Simionescu, B. C. Starcher, and N. R. Vyavahare Elastin Stabilization for Treatment of Abdominal Aortic Aneurysms Circulation, April 3, 2007; 115(13): 1729 - 1737. [Abstract] [Full Text] [PDF]

				J. S. Lee, D. M. Basalyga, A. Simionescu, J. C. Isenburg, D. T. Simionescu, and N. R. Vyavahare Elastin Calcification in the Rat Subdermal Model Is Accompanied by Up-Regulation of Degradative and Osteogenic Cellular Responses Am. J. Pathol., February 1, 2006; 168(2): 490 - 498. [Abstract] [Full Text] [PDF]

				J. N. Clark, M. F. Ogle, P. Ashworth, R. W. Bianco, and R. J. Levy Prevention of Calcification of Bioprosthetic Heart Valve Cusp and Aortic Wall With Ethanol and Aluminum Chloride Ann. Thorac. Surg., March 1, 2005; 79(3): 897 - 904. [Abstract] [Full Text] [PDF]

				F. J. Schoen and R. J. Levy Calcification of Tissue Heart Valve Substitutes: Progress Toward Understanding and Prevention Ann. Thorac. Surg., March 1, 2005; 79(3): 1072 - 1080. [Abstract] [Full Text] [PDF]

				J. M. Connolly, I. Alferiev, J. N. Clark-Gruel, N. Eidelman, M. Sacks, E. Palmatory, A. Kronsteiner, S. DeFelice, J. Xu, R. Ohri, et al. Triglycidylamine Crosslinking of Porcine Aortic Valve Cusps or Bovine Pericardium Results in Improved Biocompatibility, Biomechanics, and Calcification Resistance: Chemical and Biological Mechanisms Am. J. Pathol., January 1, 2005; 166(1): 1 - 13. [Abstract] [Full Text] [PDF]

				D. M. Basalyga, D. T. Simionescu, W. Xiong, B. T. Baxter, B. C. Starcher, and N. R. Vyavahare Elastin Degradation and Calcification in an Abdominal Aorta Injury Model: Role of Matrix Metalloproteinases Circulation, November 30, 2004; 110(22): 3480 - 3487. [Abstract] [Full Text] [PDF]

				J. Satta, J. Oiva, T. Salo, H. Eriksen, P. Ohtonen, F. Biancari, T. S. Juvonen, and Y. Soini Evidence for an altered balance between matrix metalloproteinase-9 and its inhibitors in calcific aortic stenosis Ann. Thorac. Surg., September 1, 2003; 76(3): 681 - 688. [Abstract] [Full Text] [PDF]

				M. Bailey, H. Xiao, M. Ogle, and N. Vyavahare Aluminum Chloride Pretreatment of Elastin Inhibits Elastolysis by Matrix Metalloproteinases and Leads to Inhibition of Elastin-Oriented Calcification Am. J. Pathol., December 1, 2001; 159(6): 1981 - 1986. [Abstract] [Full Text] [PDF]